BioScrip Inc. (NASDAQ:BIOS) shares saw unusually-high trading volume on Friday . Approximately 9,156,848 shares traded hands during mid-day trading, an increase of 562% from the previous session’s volume of 1,383,648 shares.The stock last traded at $2.56 and had previously closed at $2.65.

Separately, Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The company’s market capitalization is $176.08 million. The company’s 50 day moving average is $2.57 and its 200 day moving average is $2.31.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.05. During the same quarter last year, the business earned ($0.17) earnings per share. The business had revenue of $238.50 million for the quarter, compared to the consensus estimate of $232.38 million. The business’s revenue for the quarter was down 2.4% compared to the same quarter last year. On average, equities analysts forecast that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In other BioScrip news, Director Coliseum Capital Management, L bought 4,200,000 shares of the company’s stock in a transaction on Wednesday, June 22nd. The shares were bought at an average cost of $2.00 per share, with a total value of $8,400,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David W. Golding bought 12,500 shares of the company’s stock in a transaction on Friday, June 17th. The shares were acquired at an average cost of $2.48 per share, for a total transaction of $31,000.00. Following the completion of the acquisition, the director now directly owns 42,500 shares of the company’s stock, valued at approximately $105,400. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Gamco Investors INC. ET AL raised its position in BioScrip Inc. (NASDAQ:BIOS) by 1.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 864,850 shares of the company’s stock after buying an additional 12,250 shares during the period. Gamco Investors INC. ET AL owned approximately 1.26% of BioScrip worth $1,513,000 at the end of the most recent reporting period.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.